Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma

Frontiers in Bioscience

Volumn 8, Issue , 2003, Pages

  Ushio, Yukitaka ^a,b   Tada, Kenji ^a   Shiraishi, Shoji ^a   Kamiryo, Takanori ^a   Shinojima, Naoki ^a   Kochi, Masato ^a   Saya, Hideyuki ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Anaplastic Astrocytoma; EGFR; Glioblastoma; MDM2; p16; p53; PTEN; Review; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN MDM2; PROTEIN P16; PROTEIN P53; PTEN PROTEIN;

AGE; ASTROCYTE; CANCER SURVIVAL; CELL TRANSFORMATION; CHROMOSOME 10; CORRELATION ANALYSIS; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC DISORDER; GLIOBLASTOMA; HUMAN; MALIGNANT TRANSFORMATION; PROGNOSIS; REVIEW;

EID: 3142658180     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Louis D. N, E. C. Holland & J. G. Cairncross: Glioma classification: a molecular reappraisal. Am J Pathol 159, 779-86 (2001)
2. Ichimura K, M. B. Bolin, H. M. Goike, E. E. Schmidt, A. Moshref & V. P. Collins: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60, 417-424 (2000)
3. Rasheed B. K, R. E. McLendon, J. E. Herndon, H. S. Friedman, A. H. Friedman, D. D. Bigner & S. H. Bigner: Alterations of the TP53 gene in human gliomas. Cancer Res 54, 1324-1330 (1994)
4. Louis D. N: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53, 11-21 (1994)
5. Ohgaki H, B. Schauble, A. zur Hausen, K. von Ammon & P. Kleihues: Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 427, 113-118 (1995)
6. Pollack I. F, R. L. Hamilton, S. D. Finkelstein, J. W. Campbell, A. J. Martinez, R. N. Sherwin, M. E. Bozik & S. M. Gollin: The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57, 304-309 (1997)
7. Watanabe K, O. Tachibana, Y. Yonekawa, P. Kleihues & H. Ohgaki: Role of gemistocytes in astrocytoma progression. Lab Invest 76, 277-284 (1997)
8. Tada M, R. Matsumoto, R. D. Iggo, R. Onimaru, H. Shirato, Y. Sawamura & Y. Shinohe: Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 58, 1793-1797 (1998)
9. Schiebe M, P. Ohneseit, W. Hoffmann, R. Meyermann, H. P. Rodemann & M. Bamberg: Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol 49, 197-203 (2000)
10. Kraus J. A, M. Wenghoefer, N. Glesmann, S. Mohr, M. Beck, M. C. Schmidt, R. Schroder, U. Berweiler, W. Roggendorf, S. Diete, K. Dietzmann, K. Heuser, B. Muller, R. Fimmers, A. von Deimling & U. Schlegel: TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neurooncol 52, 263-272 (2001)
11. Newcomb E. W, H. Cohen, S. R. Lee, S. K. Bhalla, J. Bloom, R. L. Hayes & D. C. Miller: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8, 655-667 (1998)
12. Shiraishi S, K. Tada, H. Nakamura, K. Makino, M. Kochi, H. Saya, J. Kuratsu & Y. Ushio: Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer, (in press)
13. Rubio M. P, A. von Deimling, D. W. Yandell, O. D. Wiestler, J. F. Gusella & D. N. Louis: Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 53, 3465-3467 (1993)
14. Matsumoto R, M. Tada, M. Nozaki, C. L. Zhang, Y. Sawamura & H. Abe: Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 58, 609-613 (1998)
15. Kraus A, F. Neff, M. Behn, M. Schuermann, K. Muenkel & J. Schlegel: Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells. Int J Cancer 80, 930-934 (1999)
16. Biernat W, P. Kleihues, Y. Yonekawa & H. Ohgaki: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56, 180-185 (1997)
17. Fulci G, M. Labuhn, D. Maier, Y. Lachat, O. Hausmann, M. E. Hegi, R. C. Janzer, A. Merlo & E. G. Van Meir: p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19, 3816-3822 (2000)
18. Freedman D. A, L. Wu & A. J. Levine: Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55, 96-107 (1999)
19. Reifenberger G, L. Liu, K. Ichimura, E. E. Schmidt & V. P. Collins: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53, 2736-2739 (1993)
20. Reifenberger G, J. Reifenberger, K. Ichimura & V. P. Collins: Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site. Cancer Res 55, 731-734 (1995)
21. Korkolopoulou P, P. Christodoulou, K. Kouzelis, M. Hadjiyannakis, A. Priftis, G. Stamoulis, A. Seretis & E. Thomas-Tsagli: MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 75, 1269-1278 (1997)
22. Rainov N. G, K. U. Dobberstein, H. Bahn, H. J. Holzhausen, C. Lautenschlager, V. Heidecke & W. Burkert: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 35, 13-28 (1997)
23. Hunter S. B, K. Abbott, V. A. Varma, J. J. Olson, D. W. Barnett & C. D. James: Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J Neuropathol Exp Neurol 54, 57-64 (1995)
24. Galanis E, J. Buckner, D. Kimmel, R. Jenkins, B. Alderete, J. O'Fallon, C. H. Wang, B. W. Scheithauer & C. D. James: Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 13, 717-724 (1998)
25. Olson J. J, D. Barnett, J. Yang, R. Assietti, G. Cotsonis & C. D. James: Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 4, 215-222 (1998)
26. Kamb A, N. A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S. V. Tavtigian, E. Stockert, R. S. Day, 3rd, B. E. Johnson & M. H. Skolnick: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440 (1994)
27. Nobori T, K. Miura, D. J. Wu, A. Lois, K. Takabayashi & D. A. Carson: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756 (1994)
28. Giani C & G. Finocchiaro: Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 54, 6338-6339 (1994)
29. Schmidt E. E, K. Ichimura, G. Reifenberger & V. P. Collins: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54, 6321-6324 (1994)
30. Ichimura K, E. E. Schmidt, H. M. Goike & V. P. Collins: Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13, 1065-1072 (1996)
31. Walker D. G, W. Duan, E. A. Popovic, A. H. Kaye, F. H. Tomlinson & M. Lavin: Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 55, 20-23 (1995)
32. Moulton T, G. Samara, W. Y. Chung, L. Yuan, R. Desai, M. Sisti, J. Bruce & B. Tycko: MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146, 613-619 (1995)
33. Ueki K, Y. Ono, J. W. Henson, J. T. Efird, A. von Deimling & D. N. Louis: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56, 150-153 (1996)
34. Ono Y, T. Tamiya, T. Ichikawa, K. Kunishio, K. Matsumoto, T. Furuta, T. Ohmoto, K. Ueki & D. N. Louis: Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 55, 1026-1031 (1996)
35. Burns K. L, K. Ueki, S. L. Jhung, J. Koh & D. N. Louis: Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57, 122-130 (1998)
36. Newcomb E. W, M. Alonso, T. Sung & D. C. Miller: Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. Hum Pathol 31, 115-119 (2000)
37. James C. D, E. Galanis, L. Frederick, D. W. Kimmel, J. M. Cunningham, P. J. Atherton-Skaff, J. R. O'Fallon, R. B. Jenkins, J. C. Buckner, S. B. Hunter, J. J. Olson & B. W. Scheithauer: Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int J Oncol 15, 547-553 (1999)
38. Kamiryo T, K. Tada, S. Shiraishi, N. Shinojima, H. Nakamura, M. Kochi, J. Kuratsu, H. Saya & Y. Ushio: Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J Neurosurg 96, 815-822 (2002)
39. Kamijo T, F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld & C. J. Sherr: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659 (1997)
40. Zhang Y, Y. Xiong & W. G. Yarbrough: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734 (1998)
41. Kraus J. A, N. Glesmann, M. Beck, D. Krex, T. Klockgether, G. Schackert & U. Schlegel: Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol 48, 89-94 (2000)
42. Alleyne C. H, Jr., J. He, J. Yang, S. B. Hunter, G. Cotsonis, C. D. James & J. J. Olson: Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Int J Oncol 14, 1111-1116 (1999)
43. Puduvalli V. K, A. P. Kyritsis, K. R. Hess, M. L. Bondy, G. N. Fuller, G. P. Kouraklis, V. A. Levin & J. M. Bruner: Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol 17, 963-969 (2000)
44. Kirla R, E. Salminen, S. Huhtala, J. Nuutinen, L. Talve, H. Haapasalo & H. Kalim: Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy. J Neurooncol 46, 71-80 (2000)
45. Labuhn M, G. Jones, E. J. Speel, D. Maier, C. Zweifel, O. Gratzl, E. G. Van Meir, M. E. Hegi & A. Merlo: Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. Oncogene, 20, 1103-1109 (2001)
46. Perry A, T. Nobori, N. Ru, K. Anderl, T. J. Borell, G. Mohapatra, B. G. Feuerstein, R. B. Jenkins & D. A. Carson: Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 56, 999-1008 (1997)
47. Merlo A, J. G. Herman, L. Mao, D. J. Lee, E. Gabrielson, P. C. Burger, S. B. Baylin & D. Sidransky: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1, 686-692 (1995)
48. Costello J. F, M. S. Berger, H. S. Huang & W. K. Cavenee: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56, 2405-2410 (1996)
49. Fueyo J, C. Gomez-Manzano, J. M. Bruner, Y. Saito, B. Zhang, W. Zhang, V. A. Levin, W. K. Yung & A. P. Kyritsis: Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13, 1615-1619 (1996)
50. Kyritsis A. P, B. Zhang, W. Zhang, M. Xiao, H. Takeshima, M. L. Bondy, J. E. Cunningham, V. A. Levin & J. Bruner: Mutations of the p16 gene in gliomas. Oncogene 12, 63-67 (1996)
51. Li Y. J, K. Hoang-Xuan, J. Y. Delattre, M. Poisson, G. Thomas & R. Hamelin: Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11, 597-600 (1995)
52. Schmidt E. E, K. Ichimura, K. R. Messerle, H. M. Goike & V. P. Collins: Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer 75, 2-8 (1997)
53. Hegi M. E, A. zur Hausen, D. Ruedi, G. Malin & P. Kleihues: Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer 73, 57-63 (1997)
54. Perry A, K. Anderl, T. J. Borell, D. W. Kimmel, C. H. Wang, J. R. O'Fallon, B. G. Feuerstein, B. W. Scheithauer & R. B. Jenkins: Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am J Clin Pathol 112, 801-809 (1999)
55. Wang S. I, J. Puc, J. Li, J. N. Bruce, P. Cairns, D. Sidransky & R. Parsons: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57, 4183-4186 (1997)
56. Rasheed B. K, T. T. Stenzel, R. E. McLendon, R. Parsons, A. H. Friedman, H. S. Friedman, D. D. Bigner & S. H. Bigner: PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57, 4187-4190 (1997)
57. Ichimura K, E. E. Schmidt, A. Miyakawa, H. M. Goike & V. P. Collins: Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 22, 9-15 (1998)
58. Schmidt E. E, K. Ichimura, H. M. Goike, A. Moshref, L. Liu & V. P. Collins: Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol 58, 1170-1183 (1999)
59. Li J, C. Yen, D. Liaw, K. Podsypanina, S. Bose, S. I. Wang, J. Puc, C. Miliaresis, L. Rodgers, R. McCombie, S. H. Bigner, B. C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M. H. Wigler & R. Parsons: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947 (1997)
60. Yamaguchi F, H. Saya, J. M. Bruner & R. S. Morrison: Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci U S A 91, 484-488 (1994)
61. Mollenhauer J, S. Wiemann, W. Scheurlen, B. Korn, Y. Hayashi, K. K. Wilgenbus, A. von Deimling & A. Poustka: DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 17, 32-39 (1997)
62. Chernova O. B, R. P. Somerville & J. K. Cowell: A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene 17, 2873-2881 (1998)
63. Nakamura H, M. Yoshida, H. Tsuiki, K. Ito, M. Ueno, M. Nakao, K. Oka, M. Tada, M. Kochi, J. Kuratsu, Y. Ushio & H. Saya: Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene 16, 1009-1019 (1998)
64. Steck P. A, M. A. Pershouse, S. A. Jasser, W. K. Yung, H. Lin, A. H. Ligon, L. A. Langford, M. L. Baumgard, T. Hattier, T. Davis, C. Frye, R. Hu, B. Swedlund, D. H. Teng & S. V. Tavtigian: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15, 356-362 (1997)
65. Li D. M & H. Sun: TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57, 2124-2129 (1997)
66. Cantley L. C & B. G. Neel: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96, 4240-4245 (1999)
67. Di Cristofano A & P. P. Pandolfi: The multiple roles of PTEN in tumor suppression. Cell 100, 387-390 (2000)
68. Tamura M, J. Gu, K. Matsumoto, S. Aota, R. Parsons & K. M. Yamada: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280, 1614-1617 (1998)
69. Wen S, J. Stolarov, M. P. Myers, J. D. Su, M. H. Wigler, N. K. Tonks & D. L. Durden: PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A 98, 4622-4627 (2001)
70. Lin H, M. L. Bondy, L. A. Langford, K. R. Hess, G. L. Delclos, X. Wu, W. Chan, M. A. Pershouse, W. K. Yung & P. A. Steck: Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 4, 2447-2454 (1998)
71. Sano T, H. Lin, X. Chen, L. A. Langford, D. Koul, M. L. Bondy, K. R. Hess, J. N. Myers, Y. K. Hong, W. K. Yung & P. A. Steck: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59, 1820-1824 (1999)
72. Tada K, S. Shiraishi, T. Kamiryo, H. Nakamura, H. Hirano, J. Kuratsu, M. Kochi, H. Saya & Y. Ushio: Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg 95, 651-659 (2001)
73. Maier D, Z. Zhang, E. Taylor, M. F. Hamou, O. Gratzl, E. G. Van Meir, R. J. Scott & A. Merlo: Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 16, 3331-3335 (1998)
74. Duerr E. M, B. Rollbrocker, Y. Hayashi, N. Peters, B. Meyer-Puttlitz, D. N. Louis, J. Schramm, O. D. Wiestler, R. Parsons, C. Eng & A. von Deimling: PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16, 2259-2264 (1998)
75. Raffel C, L. Frederick, J. R. O'Fallon, P. Atherton-Skaff, A. Perry, R. B. Jenkins & C. D. James: Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 5, 4085-4090 (1999)
76. Zhou X. P, Y. J. Li, K. Hoang-Xuan, P. Laurent-Puig, K. Mokhtari, M. Longy, M. Sanson, J. Y. Delattre, G. Thomas & R. Hamelin: Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 84, 150-154 (1999)
77. Schmidt M. C, S. Antweiler, N. Urban, W. Mueller, A. Kuklik, B. Meyer-Puttlitz, O. D. Wiestler, D. N. Louis, R. Fimmers & A. von Deimling: Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61, 321-328 (2002)
78. von Deimling A, D. N. Louis, K. von Ammon, I. Petersen, T. Hoell, R. Y. Chung, R. L. Martuza, D. A. Schoenfeld, M. G. Yasargil, O. D. Wiestler & et al.: Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 77, 295-301 (1992)
79. Libermann T. A, N. Razon, A. D. Bartal, Y. Yarden, J. Schlessinger & H. Soreq: Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 44, 753-760 (1984)
80. Libermann T. A, H. R. Nusbaum, N. Razon, R. Kris, I. Lax, H. Soreq, N. Whittle, M. D. Waterfield, A. Ullrich & J. Schlessinger: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144-147 (1985)
81. Wong A. J, S. H. Bigner, D. D. Bigner, K. W. Kinzler, S. R. Hamilton & B. Vogelstein: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 84, 6899-6903 (1987)
82. Schwechheimer K, S. Huang & W. K. Cavenee: EGFR gene amplification-rearrangement in human glioblastomas. Int J Cancer 62, 145-148 (1995)
83. Muleris M, A. Almeida, A. M. Dutrillaux, E. Pruchon, F. Vega, J. Y. Delattre, M. Poisson, B. Malfoy & B. Dutrillaux: Oncogene amplification in human gliomas: a molecular cytogenetic analysis. Oncogene 9, 2717-2722 (1994)
84. Harada K, K. Kurisu, H. Tahara, E. Tahara & T. Ide: Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J Neurosurg 93, 618-625 (2000)
85. Waha A, A. Baumann, H. K. Wolf, R. Fimmers, J. Neumann, D. Kindermann, K. Astrahantseff, I. Blumcke, A. von Deimling & U. Schlegel: Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. J Neurosurg 85, 634-641 (1996)
86. Strommer K, M. F. Hamou, H. Diggelmann & N. de Tribolet: Cellular and tumoural heterogeneity of EGFR gene amplification in human malignant gliomas. Acta Neurochir (Wien) 107, 82-87 (1990)
87. Lang F. F, D. C. Miller, M. Koslow & E. W. Newcomb: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81, 427-436 (1994)
88. Watanabe K, O. Tachibana, K. Sata, Y. Yonekawa, P. Kleihues & H. Ohgaki: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6, 217-223; discussion 223-214 (1996)
89. von Deimling A, K. von Ammon, D. Schoenfeld, O. D. Wiestler, B. R. Seizinger & D. N. Louis: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3, 19-26 (1993)
90. Lammering G, K. Valerie, P. S. Lin, R. B. Mikkelsen, J. N. Contessa, J. P. Feden, J. Farnsworth, P. Dent & R. K. Schmidt-Ullrich: Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res 7, 682-690 (2001)
91. Lund-Johansen M, R. Bjerkvig, P. A. Humphrey, S. H. Bigner, D. D. Bigner & O. D. Laerum: Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 50, 6039-6044 (1990)
92. Chakravarti A, J. S. Loeffler & N. J. Dyson: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62, 200-207 (2002)
93. Wong A. J, J. M. Ruppert, S. H. Bigner, C. H. Grzeschik, P. A. Humphrey, D. S. Bigner & B. Vogelstein: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89, 2965-2969 (1992)
94. Ekstrand A. J, N. Sugawa, C. D. James & V. P. Collins: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 89, 4309-4313 (1992)
95. Wang X. Y, D. I. Smith, L. Frederick & C. D. James: Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences. Oncogene 16, 191-195 (1998)
96. Frederick L, X. Y. Wang, G. Eley & C. D. James: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60, 1383-1387 (2000)
97. Nishikawa R, X. D. Ji, R. C. Harmon, C. S. Lazar, G. N. Gill, W. K. Cavenee & H. J. Huang: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91, 7727-7731 (1994)
98. Nagane M, A. Levitzki, A. Gazit, W. K. Cavenee & H. J. Huang: Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 95, 5724-5729 (1998)
99. Simmons M. L, K. R. Lamborn, M. Takahashi, P. Chen, M. A. Israel, M. S. Berger, T. Godfrey, J. Nigro, M. Prados, S. Chang, F. G. Barker, 2nd & K. Aldape: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61, 1122-1128 (2001)
100. Barker F. G, 2nd, M. L. Simmons, S. M. Chang, M. D. Prados, D. A. Larson, P. K. Sneed, W. M. Wara, M. S. Berger, P. Chen, M. A. Israel & K. D. Aldape: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51, 410-418 (2001)
101. Feldkamp M. M, P. Lala, N. Lau, L. Roncari & A. Guha: Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45, 1442-1453 (1999)
102. Leenstra S, N. T. Oskam, E. H. Bijleveld, D. A. Bosch, D. Troost & T. J. Hulsebos: Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 79, 159-165 (1998)